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Association of Circulating Ceramides With Cardiac Structure and
Function in the Community: The Framingham Heart Study
Chike C. Nwabuo, MD, MPH; Meredith Duncan, MA; Vanessa Xanthakis, PhD; Linda R. Peterson, MD; Gary F. Mitchell, MD;
David McManus, MD; Susan Cheng, MD, MPH; Ramachandran S. Vasan, MD
Background-—A higher circulating plasma ceramide ratio (C16:0/C24:0) is associated with an increased risk of heart failure, even after
accounting for standard risk factors including lipid markers. However, the pathobiological mechanisms that underlie this association are
incompletely understood. We tested the hypothesis that plasma ceramide ratio (C16:0/C24:0) is associated with adverse cardiac
remodeling in the community.
Methods and Results-—We evaluated 2652 Framingham Offspring Study participants (mean age, 669 years; 55% women) who
attended their eighth examination cycle and underwent routine echocardiography and liquid chromatography–tandem mass
spectrometry–based assays for circulating ceramide concentrations. We used multivariable linear regression models to relate C16:0/
C24:0 (independent variable) to the following echocardiographic measures (dependent variables; separate models for each): left
ventricular mass, left ventricular ejection fraction, left atrial emptying fraction, left atrial end-systolic volume, E/e0 (a measure of left
ventricular diastolic function), and left ventricular global circumferential and longitudinal strain by speckle-tracking echocardiography. In
multivariable-adjusted analyses, higher C16:0/C24:0 per standard deviation increment was associated with lower left ventricular ejection
fraction (0.991-fold change in left ventricular ejection fraction; P=0.0004), worse global circumferential strain (b=0.34, P=0.004), higher
left atrial end-systolic volume (b=2.48, p<0.0001), and lower left atrial emptying fraction (0.99-fold change; P<0.0001). The C16:0/C24:0
ratio was not associated with either E/e0 or global longitudinal strain, and the association with higher left ventricular mass was rendered
statistically nonsignificant upon correction for multiple comparisons.
Conclusions-—Our cross-sectional observations in a large community-based sample are consistent with a potential detrimental impact of
higher ceramide ratio (C16:0/24:0) on cardiac remodeling traits, which may partly explain the associations of these molecular species
with clinical heart failure. ( J Am Heart Assoc. 2019;8:e013050. DOI: 10.1161/JAHA.119.013050.)
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H eart failure (HF) remains a leading cause of morbidity andmortality, affecting 6.5 million Americans, and its preva-
lence is expected to rise with the aging of the US population.1
Given the substantial and rising burden of HF, ongoing efforts
are needed to uncover novel mechanistic pathways that may
underlie disease pathogenesis and progression. One area of
recent interest is the role of plasma ceramide biomarkers in the
pathogenesis of cardiovascular disease (CVD), including HF.
Ceramides are bioactive lipids with a sphingoid base and a fatty
acyl chain that are present in cell membranes and plasma, and
have major influences on cellular signaling, differentiation,
senescence, and programmed cell death.2 Ceramide synthases
facilitate variable acetylation of the sphingoid base, producing a
spectrum of ceramide molecular species.2 Expression and
biomolecular effects of ceramides can vary on the basis of
detectable relative proportions of distinct circulating ceramide
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species and the CVD risk profile.3 Recent studies have focused,
therefore, on analyzing the ratio of select ceramides, such as the
ratio of long-chain to very-long-chain ceramide species.4,5 In the
FHS (Framingham Heart Study), higher circulating levels of
ceramide 16:0 relative to ceramide 24:0 were associated with
an increased HF risk even after adjusting for standard CVD risk
factors, including blood lipid levels.5 These findings have been
supported recently by a report from the CHS (Cardiovascular
HealthStudy),whichnoted that lowercirculatingconcentrations
of fatty acids with 24 carbons and no unsaturated bonds, was
associated with a higher risk of HF.6 However, the mechanisms
underlying these relations are incompletely understood. In this
context, it is widely accepted that antecedent alterations in
cardiac structure and function (cardiac remodeling) antedate
the onset of overt HF.7,8Accordingly, we investigated the
association between the plasma ceramide ratio (C16:0/
C24:0) and echocardiographic measures of cardiac structure
and function in a large community-based sample where both
sets of measures were contemporaneously assessed.
Methods
Study Design and Participant Selection
The objectives and study design of the FOS (Framingham
Offspring Study) have been published previously.9 Briefly,
offspring of the original FHS cohort and their spouses were
enrolled in the FOS in 1971, and participants have been
evaluated approximately every 4 years. Of the 3021 atten-
dees at the eighth examination cycle (2005–2008), we
excluded participants who did not have plasma samples for
ceramide quantification (n=177) and those with missing
covariates (n=192), yielding an analytic sample size of 2652
study participants who underwent routine transthoracic
echocardiography and phlebotomy to obtain plasma samples
for targeted measurement of circulating ceramide species.
The institutional review boards at the Boston University
Medical Center and the Washington University School of
Medicine, St. Louis, Missouri, approved the study protocols,
and all participants provided written informed consent. FOS
data and materials in the current study will be made publicly
available through the Biologic Specimen and Data Reposi-
tories Information Coordinating Center (BioLINCC) of the
National Heart Lung and Blood Institute, Bethesda.
Measurement of Plasma Ceramides
The targeted plasma ceramide assay and quantification of
C24:0 and C16:0 in the FHS Offspring cohort have been
previously reported and demonstrated an excellent repro-
ducibility profile.5 Briefly, plasma ceramides were obtained
using a sensitive, accurate, and high-throughput liquid chro-
matography–mass spectrometry assay to quantify the long-
chain (C16:0) and the very-long-chain (C24:0) ceramides in
fasting plasma samples. The coefficients of variation for
C16:0 and C24:0 assays were 7.8% and 6.9%, respectively,
whereas the interassay and intra-assay accuracy values were
within 3.2% and 4.9% deviation for C16:0 and C24:0
ceramides, respectively. Ten percent of samples were tested
in duplicate for quality assurance purposes.
Covariates
FHS Offspring study participants underwent a detailed
medical history, physical examination, and laboratory assess-
ment for CVD risk factors using methods described previ-
ously.10,11 Briefly, systolic and diastolic blood pressure were
assessed by an FHS physician, and weight and height by
technicians using standardized protocols. Participants were
considered to be current smokers if they reported smoking ≥1
cigarettes on a daily basis during the year preceding their FHS
examination. Assays were performed on fasting biosamples
using standard enzymatic methods for blood glucose, serum
creatinine, serum total cholesterol, and high-density lipopro-
tein cholesterol. Estimated glomerular filtration rate was
calculated using the chronic kidney disease epidemiology
collaboration equation.12
Echocardiographic Measures
Echocardiographic assessment in the FHS Offspring Study at
the eighth examination cycle has been described previ-
ously.11,13,14 For our investigation, we evaluated the following
Clinical Perspective
What Is New?
• We used a high-throughput liquid chromatography–mass
spectrometry assay to quantify ratios of ceramide molecular
species in the plasma and subsequently assessed their
relations to echocardiographic measures of cardiac remod-
eling.
• Data from the Framingham Offspring Study demonstrate
that higher plasma ceramide ratio (C16:0/24:0) is associ-
ated with potentially detrimental changes in echocardio-
graphic measures of cardiac structure and function.
What Are the Clinical Implications?
• Our study observations support the notion that the asso-
ciation between higher ceramide ratio (C16:0/24:0) and the
subsequently increased risk of clinical heart failure may be
partly explained by relations with unfavorable subclinical
cardiac structural and functional alterations.
DOI: 10.1161/JAHA.119.013050 Journal of the American Heart Association 2
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echocardiographic measures: left ventricular (LV) mass (LVM),
LV ejection fraction (LVEF), left atrial (LA) emptying fraction
(LAEF), LA end-systolic volume (LAVes), ratio of mitral inflow
velocity to early diastolic mitral annular velocity (E/e0), LV
global longitudinal strain (GLS), and global circumferential
strain (GCS). Using Digisonics DigiView System Software
(version 3.7.9.3; Digisonics Inc, Houston, TX) and digitized
images, LV volumes were measured by Simpson’s method. LA
maximum and minimum volumes were obtained by averaging
the respective volumes in apical 2- and 4-chamber views that
were measured using the area-length method.15 Early peak
systolic mitral annulus velocity was measured at the lateral
mitral annulus using Doppler tissue imaging. Transmitral
Doppler flow velocities were recorded using a standardized
protocol. Repeated analysis of LV diastolic function measures
yielded interobserver correlation with coefficients of >0.97.
We used an offline speckle-tracking software package (2D
Cardiac Performance Analysis v1.1; TomTec Imaging Systems,
Unterschleißheim, Germany) to analyze LV myocardial defor-
mation, including GLS and GCS, according to a standardized
protocol with excellent reproducibility.16 GCS and GLS are
markers of myocardial deformation, and more positive values
indicate worse systolic function. Lower values of LAEF
indicate worse LA function.
Statistical Analyses
Descriptive characteristics of study participants were sum-
marized as meanSD or as median (25th, 75th percentile) for
continuous variables, while categorical variables were sum-
marized using proportions. Skewed echocardiographic mea-
sures were transformed by using natural logarithms to
normalize their distributions.
We used multivariable linear regression to relate the
plasma ceramide ratio C16:0/24:0 (independent variable) to
the following echocardiographic measures (dependent vari-
ables, separate model for each): LVM, LVEF, GLS, GCS, E/e0,
LAVes, and LAEF. Multivariable regression models were
adjusted for the following covariates: age, sex, resting heart
rate, height, weight, diabetes mellitus, systolic blood pressure,
antihypertensive medication use, current smoking, and esti-
mated glomerular filtration rate the ratio of total to high-
density lipoprotein cholesterol. We plotted cubic splines with
4 knots at the 5th, 25th, 75th, and 95th percentiles with a
reference equal to the median C16:0/C24:0 value (0.07) to
visualize the associations between C16:0/24:0 and echocar-
diography measures. All analyses were performed using SAS
version 9.4 (SAS Institute, Cary, NC). A Bonferroni corrected
2-sided P<0.007 (0.05/7) was used to indicate statistical
significance to account for multiple testing. Authors (V.X. and
M.D.) had access to all the data and take responsibility for the
integrity of the analyses.
Results
Baseline Characteristics
The baseline clinical, biochemical, and echocardiographic
characteristics of our study sample are shown in Table 1.
Study participants in our sample had a mean age of
669 years, and 48.1% were men. The mean plasma
concentration of C16:0 was roughly one tenth as abundant
as that of plasma C24:0.






Systolic blood pressure, mm Hg 12817
Diastolic blood pressure, mm Hg 7410
Use of antihypertensive medication, % 47.5
Heart rate, bpm 59.610
Diabetes mellitus, % 3.1




Total cholesterol, mg/dL 186.637
Lipid lowering medication use, % 42.1
eGFR, mL/min/1.73 m2 77.816
Prior heart failure, % 2.38
Plasma ceramide concentrations
Plasma C16:0 ceramide, lg/mL 0.20.04
Plasma C24:0 ceramide, lg/mL 2.30.7
Plasma C16/24 ceramide, lg/mL 0.080.02
Echocardiographic measures
LV mass index, g 162.2 (134.5, 162.6)
LV ejection fraction, % 67.3 (62.9, 71.7)
Left atrial emptying fraction, % 48 (46, 50)
Left atrial end-systolic volume, mL 56.819.3
LV global longitudinal strain, % 20.63
LV global circumferential strain, % 31.96
E/e0 6.6 (5.5, 8.1)
Values are meanstandard deviation, median (Q1, Q3), or percentage. E/e0 indicates
mitral inflow velocity to early diastolic mitral annular velocity; eGFR, estimated
glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density
lipoprotein cholesterol; LV, left ventricular.
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Circulating Ceramide Ratio Cardiac Structure and
Function
Results from multivariable linear regression models relating
ceramide ratio to echocardiographic traits are shown in Table 2.
In multivariable-adjusted models, higher ceramide ratio C16:0/
C24:0 was associated with lower LVEF, worse (more positive) LV
GCS, lower LAEF, higher LAVes, and a higher LVM, although the
association with LVM was no longer statistically significant after
adjustment for multiple comparisons. C16:0/24:0 ratio was not
associated with either E/e0 or GLS. Figure S1 shows the least
squared mean plots per tertile of C16:0/24:0 ratio.
In the Figure, restricted cubic splines illustrating the
association between C16:0/24:0 ratio and echocardiography
measures (LAEF, GCS, LVM, and LVEF) are shown. Higher
C16:0/24:0 ratio above the set reference level showed an
approximately linear relation with LAEF, LVM, and LVEF,
whereas the association with GCS was monotonic.
Discussion
Principal Findings
In a large community-based sample, we observed that a
higher circulating plasma C16:0/C24:0 ceramide ratio was
cross-sectionally associated with alterations in cardiac struc-
ture and function, including higher LAVes, lower LV systolic
function (determined by LVEF and LV GCS), lower LA function
(assessed by LAEF), and a propensity toward an association
with LVM upon correction for multiple comparisons. However,
a higher C16:0/C24:0 ceramide ratio was not significantly
associated with either E/e0 or GLS. Our findings raise the
possibility that the association of higher circulating ceramide
ratio (C16:0/C24:0) with an increased HF risk may in part be
mediated by the association between specific ceramide
species and measures of LV as well as LA remodeling.
Comparison With Published Literature
To our knowledge, this is the first investigation to explore the
relations between plasma ceramide concentration ratios and
cardiac structure and function in a community-based sample.
Circulating ceramide species are less abundant than choles-
terol in plasma and have been challenging to assay precisely in
the past. In recent years, the advent of liquid chromatography–
mass spectrometry techniques has facilitated the more accu-
rate measurement of several plasma ceramide molecular
species. It is now increasingly recognized that distinct ceramide
acyl chain lengths play important roles in biophysical properties
of membranes, cell signaling, and apoptosis, with long-chain
and very-long-chain ceramides (including C16:0 and C24:0)
being the predominant ceramides in mammalian tissues.17–19
C16:0 promotes programmed cell death by a cascade of events
involving ceramide-mediated channels and a loss of mitochon-
drial outer membrane integrity that facilitate the release of
cytochrome c and other proapoptotic proteins into the
cytoplasm, ultimately resulting in mitochondria-induced apop-
tosis.2,18 In contrast, C24:0 interferes with C16:0 ceramide-
associated channel formation in the mitochondria and has
predominantly antiapoptotic effects.20 These species are also
linked by intermediary metabolism enzymatic pathways.20 For
example, in cells with selective knockdown of ceramide
synthetase-2 (which catalyzes the generation of very-long-
chain ceramides, including C24:0) there was near elimination of
C24:0 ceramide and higher C16:0 ceramide levels.18 Further-
more, the concentration or expression of plasma ceramides and
their resultant effects are modified by prevalent CVD risk
burden such as diabetes mellitus and smoking.4,5 To mitigate
these influences, rather than utilizing total ceramide levels, a
ceramide ratio consisting of the indexation of the long-chain
ceramide species by very-long-chain ceramide species such as
C16:0/24:0 ratio has emerged as a marker that provides
greater information than either species alone in ceramide-
related analysis.3,4 Multiple lines of evidence support the
association of alterations in concentrations of plasma ceramide
species with adverse cardiovascular outcomes and mortality in
patients with prior CVD6,21–23 and in asymptomatic community-
dwelling individuals.5 These studies demonstrate the additional
prognostic value of specific plasma ceramides for predicting
CVD risk beyond standard CVD risk factors, including plasma
lipid levels.5 In one study of individuals with coronary artery




(Standard Error) eb̂ P Value
LV ejection fraction* 0.009 (0.002) 0.991 0.0004†
LV global circumferential strain 0.34 (0.12) NA 0.004†
LV global longitudinal strain 0.07 (0.06) NA 0.26
E/e0* 0.006 (0.005) 1.006 0.26
Left atrial emptying fraction* 0.008 (0.002) 0.992 <0.0001†
Left atrial end-systolic volume 2.48 (0.4) NA <0.0001†
LV mass* 0.009 (0.004) 1.009 0.02
Multivariable linear regression showing the relation between C16:0/C24:0 and
echocardiographic measures (dependent variable). Beta estimates represent change in
echocardiography variable per 1 SD increment in ceramide ratio. Models were adjusted
for age, sex, heart rate, height, weight, diabetes mellitus, systolic blood pressure,
antihypertensive medication use, current smoking, estimated glomerular filtration rate,
and the ratio of total to high-density lipoprotein cholesterol. E/e0 indicates mitral inflow
velocity to early diastolic mitral annular velocity; LV, left ventricular; NA, not applicable.
*These dependent variables were natural logarithmically transformed to satisfy the
normality assumption of linear regression models. In these models eb̂ represents the fold
change in Y per standard deviation increase in C16:0/C24:0. More positive global strain
values signify worse LV systolic function.
†Denotes associations that retain statistical significance following a Bonferroni
correction for multiple testing.
DOI: 10.1161/JAHA.119.013050 Journal of the American Heart Association 4
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disease, there were more pronounced differences in circulating
ceramide profiles than in the standard lipid markers when
subjects who died during follow-up were compared with those
who survived.4 Elevated plasma total ceramide levels have also
been reported to be associated with New York Heart Associ-
ation functional classes in individuals with HF and reduced
ejection fraction.24 Similarly, in patients with HF, LV assist
device placement reduced the detectable level of total
ceramides present in the myocardium.25 In the CHS, a lower
plasma level of the 24:0 fatty acid, lignoceric acid, was also
associatedwith a higher risk of HF,which is consistent with data
from experimental studies.6 Similarly, in the FHS, we previously
reported that a higher level of C16:0 in relation to C24:0 was
associated with an increased risk of incident HF. The present
investigation is consistent with these findings and importantly
offers additional insight into underlying mechanisms by
demonstrating an association of higher circulating ceramide
ratio (C16:0/C24:0) with adverse cardiac structural and
functional alterations. Antecedent subclinical impairment in
LV strain by speckle-tracking echocardiography, LVEF, LV
mass, and LA function have been widely established as strong
independent predictors of future HF, CVD, and all-cause
mortality.7,13,14 In the present study, there was no association
between C16:0/C24:0 and E/e0 (a surrogate for LV diastolic
dysfunction). The reason for this observed lack of association
with E/e0 is not entirely clear but may be partly related to the
Figure. Restricted cubic splines plots showing the relations between ceramide ratio and LVEF, LAEF, global circumferential strain, and LV
mass. Shaded areas represent the 95% CIs. The reference value in each panel is set to the median C16:0/C24:0 ratio of 0.07. The yellow
hashed line serves as a reference line of “no association.” LAEF indicates left atrial emptying fraction; LV, left ventricular; LVEF, left ventricular
ejection fraction.
DOI: 10.1161/JAHA.119.013050 Journal of the American Heart Association 5
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narrow distribution of E/e0 ratio in our relatively healthy
sample with a median E/e0 of 6.6 (which is well below
thresholds for LV diastolic dysfunction).26 Although there was
no association of the ceramide ratio with E/e0, we observed
statistically strong associations between C16:0/C24:0 and
higher LAVes and lower LAEF—a sensitive marker for subclin-
ical LA remodeling that may identify individuals at high risk for
HF independent of LVEF.27,28 Furthermore, we observed
associations between C16:0/C24:0 and GCS but not with
GLS. It is conceivable that distinct aspects of myocardial
deformation may have differential associations with various
biomarkers of CVD risk.14 Our observation of an association
with GCS but not with GLS may suggest potential involvement
of mesocardial more than endocardial myocardial function, a
speculative premise that warrants further investigation.
Potential Mechanisms
There are several plausible mechanisms that support a
relation between the circulating C16:0/C24:0 and subclinical
cardiac remodeling and dysfunction. Sphingosine-1-phos-
phate, a signaling molecule formed by the phosphorylation
of sphingosine, is interconvertible with ceramides.29 Sphin-
gosine-1-phosphate can function to inhibit apoptosis and is
also reported to suppress the proapoptotic effects of
ceramides.29,30 In porcine models, administration of sphin-
gosine-1-phosphate receptor agonist reduced post–myocar-
dial infarction LV remodeling and improved LV systolic
function.31 Sphingosine-1-phosphate is also a constituent of
high-density lipoprotein and a contributor to many of the
beneficial effects of high-density lipoprotein on the heart and
circulatory system.32
Animal and human studies have shown that total ceramides,
and C16:0 in particular, are related to markers of inflammation
(like interleukin-6), insulin resistance, and diabetes mellitus
through activation of inflammatory mediators such as tumor
necrosis factor-a as well as adiponectin receptor–associated
ceramidase activity.33,34 In a dietary study, consumption of a
Western diet increased total ceramide content in myocardium
with normal geometry and LV hypertrophy.35Aging, smoking,
and prevalent CVD are also associated with higher ceramide
ratio (C16:0/C24:0) in the community.5 Sphingosine, which is
the main constituent of the ceramide backbone, has been
reported to mediate the negative inotropic effects of tumor
necrosis factor-a in adult mammalian cardiomyocytes.36 In
in vitro andmurine studies, exogenous cell-permeable ceramide
can induce cardiomyocyte apoptosis and the inhibition of serine
palmitoyl–coenzyme A transferase—which is vital for ceramide
biosynthesis—mitigated atherosclerosis development.36,37
Overall, these findings suggest that ceramides may play a
contributory role in the cardiometabolic dysfunction that
precedes cardiac remodeling and overt HF.
Strengths and Limitations
The large, well-characterized community-based sample; stan-
dardized measurement of echocardiographic measurements;
and contemporaneous assessment of ceramides with liquid
chromatography–mass spectrometry–based state-of-the art
assays strengthen our investigation. Our study sample was
mainly composed of middle-aged to elderly white men and
women of predominantly European ancestry; therefore, the
generalizability of our findings to other age or racial groups is
uncertain. Our cross-sectional study design precludes any
causal inferences.
Conclusions
In our cross-sectional investigation of a moderate-sized
community-based sample, we observed that a higher
ceramide ratio (C16:0/C24:0) was associated with potentially
unfavorable subclinical cardiac structural and functional
alterations, which may represent an important underlying
pathophysiological mechanism linking circulating ceramide
species to HF risk in the community.
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Figure S1. Least squared mean plots per tertile of C16/24 ratio for: Left ventricular (LV) 
global circumferential strain; LV mass; Left atrial emptying fraction; LV ejection fraction 
Models were adjusted for the following covariates: age, sex, heart rate, height, weight, 
diabetes, systolic blood pressure, antihypertensive medication use, current smoking, 
estimated glomerular filtration rate, and total/HDL cholesterol ratio.  
Per tertile of C16:0/24:0 ratio there was a linear trend towards worse GCS and lower 
LAEF. In contrast, there was a non-linear trend between LVM and C16:0/24:0. A 
propensity towards a trend was observed (albeit non-significant) of lower LVEF per 
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